pharmaceutical investing Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
pharmaceutical investing FDA approves IMAAVY® as first-ever treatment for warm autoimmune hemolytic anemia , representing a landmark advancement for patients
pharmaceutical investing Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
pharmaceutical investing Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
pharmaceutical investing Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
pharmaceutical investing Johnson & Johnson's RYBREVANT FASPRO receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
pharmaceutical investing Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
pharmaceutical investing Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
pharmaceutical investing Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
pharmaceutical investing Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA Robotic Surgical System
pharmaceutical investing Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
